R
Rikushi Morita
Researcher at Shiga University of Medical Science
Publications - 66
Citations - 773
Rikushi Morita is an academic researcher from Shiga University of Medical Science. The author has contributed to research in topics: Bone mineral & Bone density. The author has an hindex of 14, co-authored 66 publications receiving 756 citations. Previous affiliations of Rikushi Morita include Kyoto University.
Papers
More filters
Journal ArticleDOI
Effect of an intermittent weekly dose of human parathyroid hormone (1-34) on osteoporosis: a randomized double-masked prospective study using three dose levels.
T. Fujita,T. Inoue,H. Morii,Rikushi Morita,H. Norimatsu,Hajime Orimo,Hideaki E. Takahashi,Kichizou Yamamoto,Masao Fukunaga +8 more
TL;DR: Intermittent weekly injection of hPTH (1–34) increased lumbar BMD in osteoporosis, suggesting usefulness in the treatment of osteoporeosis.
Journal ArticleDOI
Tumor-induced vitamin D-resistant hypophosphatemic osteomalacia associated with proximal renal tubular dysfunction and 1,25-dihydroxyvitamin D deficiency.
Yasuaki Fukumoto,Seiichiro Tarui,Keiko Tsukiyama,Kikuo Ichihara,Kaname Moriwaki,Kyohei Nonaka,Tetsuya Mizushima,Yasushi Kobayashi,Shigeharu Dokoh,Masao Fukunaga,Rikushi Morita +10 more
TL;DR: Investigation of the underlying causal mechanism for osteomalacia in a 27-yr-old woman who presented with a several-year history of progressive muscle weakness and pain found impaired proximal renal tubular reabsorptive function.
Journal ArticleDOI
A comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial.
Masao Fukunaga,Kazuhiro Kushida,Hideaki Kishimoto,Masataka Shiraki,Yuji Taketani,Hiroshi Minaguchi,T. Inoue,Rikushi Morita,H. Morii,Kichizou Yamamoto,Yasuo Ohashi +10 more
TL;DR: Daily oral risedronate exhibited efficacy superior to that of intermittent cyclical etidronate (200 mg) in increasing L2–L4 BMD, and was well tolerated by Japanese patients with involutional osteoporosis.
Journal Article
Metastatic medullary thyroid cancer: localization with iodine-131 metaiodobenzylguanidine.
Teruki Sone,Masao Fukunaga,Nobuaki Otsuka,Rikushi Morita,Akira Muranaka,Shinichi Yanagimoto,Tatsushi Tomomitsu,Hiroki Nakayama,Tanekazu Harada +8 more
TL;DR: Iodine-131 MIBG may prove to be useful for scintigraphic localization and for the treatment of medullary thyroid cancer as in pheochromocytoma and neuroblastoma.
Journal ArticleDOI
A double-blind dose-ranging study of risedronate in Japanese patients with osteoporosis (a study by the Risedronate Late Phase II Research Group)
Masataka Shiraki,Masao Fukunaga,Kazuhiro Kushida,Hideaki Kishimoto,Yuji Taketani,Hiroshi Minaguchi,T. Inoue,Rikushi Morita,H. Morii,Kichizou Yamamoto,Yasuo Ohashi,Hajime Orimo +11 more
TL;DR: Risedronate was well tolerated in this 36-week study with 1- to 5-mg doses and is recommended for the treatment of involutional osteoporosis in Japanese patients.